TL;DR
A pioneering medical breakthrough is transforming lives for people who have lost their sight due to advanced age-related macular degeneration (AMD).
Recent clinical trial results have demonstrated that a tiny microchip implant, combined with specialised augmented reality glasses, is enabling previously blind patients to read again.
What is geographic atrophy?
Geographic atrophy (GA) is an advanced stage of dry AMD that affects approximately 5 million people worldwide. This progressive condition causes the deterioration and death of light-sensitive cells in the macula – the central part of the retina responsible for sharp, detailed vision.
As these cells degenerate, patients experience severe central vision loss, making everyday activities like reading, recognising faces and navigating daily life extremely challenging.
Currently, there are no conventional treatments available for this debilitating condition, making the PRIMA implant particularly significant for patients who previously had no options for vision restoration.
Introducing PRIMA: A life-changing development
The PRIMA device represents a significant advancement in artificial vision technology. This ultra-thin microchip, measuring just 2mm by 2mm and half the thickness of a human hair, is surgically placed beneath the retina during a procedure lasting approximately two hours.
The international clinical trial involved 38 participants across 17 medical centres in five European countries, including the UK, France, Italy and the Netherlands.
The results have been remarkable: 84% of patients who completed the study demonstrated meaningful improvements in their visual ability, with many regaining the capacity to read letters, numbers and words.
How the technology works
The PRIMA system combines cutting-edge technology with the body’s natural visual pathways:
- The implant: The microchip is positioned under the centre of the retina through a specialised surgical procedure
- Augmented reality glasses: Patients wear glasses fitted with a miniature video camera that captures their visual field
- Signal transmission: Images from the camera are converted and transmitted via near-infrared light to the implant
- Visual processing: The chip transforms these signals into electrical impulses that stimulate the remaining healthy retinal cells
- Brain interpretation: These signals travel through the optic nerve to the brain, where they’re interpreted as vision.
Patients also carry a small computer unit that processes the images and includes helpful features such as zoom and magnification functions, allowing them to adjust text size and improve clarity.
Real patient experiences
Sheila Irvine, a 70-year-old patient who received the implant at Moorfields Eye Hospital in London, described the experience as “out of this world.” Having lived with severe vision loss for over 15 years, she can now enjoy reading books and completing crossword puzzles – activities that bring her immense pleasure.
The rehabilitation process requires dedication and patience. Following the surgery, patients spend months learning to interpret the visual signals from their implant.
Ms Irvine noted that whilst reading isn’t simple and requires concentration, regular practice has significantly improved her abilities. She now challenges herself with increasingly difficult tasks, such as reading prescription labels and the small text on food packaging.
Clinical trial outcomes
The published results in the New England Journal of Medicine demonstrated impressive improvements. Participants were able to read an average of five additional lines on standard vision charts – equivalent to 25 more letters than before the procedure. Many patients who couldn’t even see the chart prior to surgery gained substantial visual function.
Mr Mahi Muqit, consultant vitreoretinal surgeon at Moorfields Eye Hospital and senior clinical lecturer at UCL Institute of Ophthalmology, who led the UK portion of the trial, described the results as representing “a new era” in artificial vision. He emphasised that this is the first implant demonstrated to provide patients with meaningful vision they can use in daily activities such as reading and writing.
Looking towards the future
Whilst the PRIMA implant remains in clinical trials and is not yet licensed for widespread use outside research settings, the results offer tremendous hope for the future. Experts anticipate that with continued development and regulatory approval, this technology could potentially become available through the NHS within the coming years.
The success of this trial marks a paradigm shift in how we approach vision loss from geographic atrophy. For the first time, patients with this previously untreatable condition have a genuine option for restoring functional vision and reclaiming their independence.
The importance of regular eye examinations
This breakthrough underscores the critical importance of regular comprehensive eye examinations. Early detection of AMD and monitoring its progression remain essential, even as new treatment options emerge.
If you or a loved one is experiencing changes in vision, particularly distortions in central vision or difficulty with tasks requiring fine detail, we encourage you to book an appointment with an experienced optometrist.
Whilst treatments like the PRIMA implant are still developing, early detection and management of eye conditions remain your best defence for maintaining long-term eye health.
Image Credit: BBC.
